Q-omics provides the consensus-scored DIRAS3 profile across patient tissues and cancer cell-line models. DIRAS3 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, DIRAS3 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, DIRAS3 RNA expression shows 16,160 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where DIRAS3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DIRAS3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DIRAS3 survival associations across molecular data types. DIRAS3 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DIRAS3 RNA expression–survival associations across cancer types. High DIRAS3 expression shows unfavorable associations in BLCA and LGG, but favorable associations in KIRP, THCA, BRCA and SCLC. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for DIRAS3 RNA expression.
This table summarizes DIRAS3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for DIRAS3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DIRAS3 shows lower tumor expression in KIRC, KIRP, KICH, BLCA and LIHC and higher tumor expression in THCA. The KIRC box plot shows higher DIRAS3 RNA expression in normal versus tumor tissue (log2 FC = −2.187, t-test p < 0.001).
This table shows molecular features associated with DIRAS3 in patient tissues and cancer cell lines. In patient samples, DIRAS3 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, DIRAS3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BREAST.
